KYTX · Kyverna Therapeutics, Inc. · Executive Compensation
$6.36
-0.03 (-0.47%)
At close · Oct 12
Return incl. dividend (before tax)
Market Cap
$395.18M
Shares
61.84M
Volume · Oct 12
93.77K
Avg daily vol (3M)
903.65K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Naji H. Gehchan | Chief Medical and Development Officer | $2,085,173 |
| Warner Biddle | Chief Executive Officer | $1,814,980 |
| Marc Grasso | Chief Financial Officer | $1,663,536 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Warner Biddle | Chief Executive Officer | $14,992,896 |
| Peter Maag | Former Chief Executive Officer | $1,481,230 |
| James Chung | M.D., Ph.D. Former Chief Medical Officer | $624,576 |
| Karen Walker | Chief Technology Officer | $591,360 |
| Dominic Borie | M.D., Ph.D. Former President, Research and Development | $587,840 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| James Chung | M.D., Ph.D. Former Chief Medical Officer | $1,166,122 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Greg Martini | Chief Financial Officer | Appointed | 2026-05-18 |
| Marc Grasso, M.D. | all positions that you held with the Company or any of its affiliates, including, without limitation, as an officer, manager or | Resigned | 2026-05-18 |
| Marc Grasso | principal financial officer | Resigned | 2026-05-18 |
| Marc Grasso | principal accounting officer | Resigned | 2026-05-18 |
| Gregory Martini | principal accounting officer | Appointed | 2026-05-18 |
| Gregory Martini | Chief Financial Officer | Appointed | 2026-05-18 |
| Daniel Spiegelman | member of the Board and all committees thereof | Resigned | 2026-02-24 |
| Sravan Emany | Class I director | Appointed | 2026-02-24 |
| Andrew Miller, Ph.D. | Class III director | Appointed | 2026-02-24 |
| Mayo Pujols | Chief Technology Officer | Appointed | 2026-02-03 |
| Karen Walker | Chief Technology Officer | Retired | 2026-02-03 |
| Christi Shaw | Executive Chairperson of the Board | Appointed | 2026-01-12 |
| Steve Liapis, Ph.D. | member of the Board and all committees thereof | Resigned | 2025-09-25 |
| Marc Grasso, M.D. | Chief Financial Officer | Appointed | 2025-06-30 |
| Ryan Jones | officer, manager or director | Resigned | 2025-06-30 |
| Marc Grasso | Chief Financial Officer | Appointed | 2025-06-30 |
| James Chung, M.D., Ph.D. | Chief Medical Officer | Resigned | 2024-11-26 |
| James Chung, M.D., Ph.D. | Chief Medical Officer | Resigned | 2024-11-13 |
| Mert Aktar | Class III director | Appointed | 2024-10-21 |
| Peter Maag | member of the Board | Resigned | 2024-09-16 |
| Peter Maag | CEO | Resigned | 2024-09-16 |
| Peter Maag, Ph.D. | all positions that you held with the Company or any of its subsidiaries and affiliates, including, without limitation, as an emp | Resigned | 2024-09-16 |
| Peter Maag | all positions that you held with the Company or any of its subsidiaries and affiliates, including, without limitation, as an emp | Resigned | 2024-09-16 |
| Brian Kotzin, M.D. | Board and the Audit Committee of the Board | Resigned | 2024-09-16 |
| Christi Shaw | Class II director | Appointed | 2024-09-16 |